Print Friendly, PDF & Email

NCT/Study#

NCT04093596 /

ALLO-715-101

A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: